The EUnetHTA 21 is pleased to announce the publication of their first Joint Clinical Assessment.
One of the objective of the JCA production was to test the newly developed methodological guidelines as well as the revised templates and guidelines, in EUnetHTA 21.
The JCA was conducted on the medical device Optilume® urethral drug-coated balloon (DCB), which is a urethral balloon that is precoated with an antiproliferative medicinal product (paclitaxel).
We thank everyone involved for their work on this important milestone of the project.
More information and the JCA report can be found here: https://www.eunethta.eu/d5-4/